Neurexophilin-3 Inhibitors
Neurexophilin-3 inhibitors are a class of chemical compounds that modulate the activity of Neurexophilin-3 (NXPH3), a secreted glycoprotein that is closely associated with the neurexin family of cell surface proteins. Neurexins play a significant role in synaptic organization and communication, and neurexophilins are thought to be ligands that modulate their function. Neurexophilin-3, specifically, is known for its ability to influence synaptic transmission by binding to certain subtypes of neurexins, thus affecting calcium ion influx and altering presynaptic release mechanisms. The inhibition of Neurexophilin-3 involves the disruption of this binding or interference with its secretion and localization, which could affect the synaptic architecture and the regulation of neuronal signaling. The role of Neurexophilin-3 in synaptic function is complex and not yet fully understood, but it is a subject of increasing research focus because of its potential influence on the fine-tuning of neural circuits.
Compounds classified as Neurexophilin-3 inhibitors are often designed or discovered through a combination of structure-activity relationship studies and high-throughput screening methods. These inhibitors can be small molecules, peptides, or even larger biomolecules that interact specifically with either Neurexophilin-3 or the receptor it modulates. The structural diversity of these inhibitors reflects the varied mechanisms through which they might interfere with NXPH3 activity, including competitive binding, allosteric modulation, or preventing its release from the cell. Furthermore, the specificity of these inhibitors is often determined through biochemical assays that evaluate the binding kinetics and the effect on synaptic transmission at the molecular level. Understanding how these inhibitors interact with the Neurexophilin-3-neurexin complex allows researchers to better comprehend the precise role of NXPH3 in synaptic regulation, as well as its broader implications in neural connectivity and communication.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could potentially reduce Neurexophilin-3 expression by inhibiting histone deacetylases, leading to a more condensed chromatin state which may suppress gene transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By inhibiting DNA methyltransferase, 5-Azacytidine might cause hypomethylation of gene promoter regions and could result in the decreased transcription of genes including Neurexophilin-3. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 has the potential to decrease Neurexophilin-3 expression by preventing the methylation of DNA, which can lead to a less permissive state for gene transcription. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 could downregulate Neurexophilin-3 by disrupting the interaction between acetylated histones and bromodomain-containing proteins, leading to altered expression of genes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may decrease Neurexophilin-3 expression by inhibiting MEK, which is part of the MAPK/ERK pathway that can control gene transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002's inhibition of PI3K could lead to reduced activity of downstream AKT signaling, potentially resulting in the decreased expression of Neurexophilin-3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin might inhibit Neurexophilin-3 expression by inhibiting mTORC1 signaling, which is crucial for cap-dependent translation initiation, possibly leading to reduced protein synthesis of many genes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 could lead to a decrease in Neurexophilin-3 expression by inhibiting ROCK kinase activity, which could alter the cytoskeleton and cellular processes that contribute to gene expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
By inhibiting TGF-beta receptor kinases, SB 431542 could decrease Neurexophilin-3 expression as it may disrupt downstream SMAD transcription factor phosphorylation and localization. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could reduce Neurexophilin-3 levels by inhibiting JNK, which might subsequently decrease transcription factor activity that is required for Neurexophilin-3 gene transcription. | ||||||